NLRP3 and Alzheimer disease: In light of our therapeutic dosing with VEN-02XX in the 5XFAD/Rubicon KO mice with established AD pathology32, it is plausible that blocking NLRP3 reduced Aβ deposition and spreading throughout the 9-week dosing period.